Hedera Dx focuses on advancing diagnostic technologies that enhance the accuracy and efficiency of disease detection. Their primary offering includes a proprietary platform that utilizes advanced molecular diagnostics to identify pathogens and biomarkers with high sensitivity and specificity. This technology is designed to streamline the diagnostic process, enabling faster results that can significantly impact patient care and treatment decisions. The company emphasizes the importance of precision in diagnostics, aiming to provide healthcare professionals with reliable tools to improve patient outcomes.

In addition to their diagnostic platform, Hedera Dx is committed to ongoing research and development to expand their product pipeline. They leverage cutting-edge scientific methodologies to innovate and refine their technologies, ensuring they remain at the forefront of the diagnostic industry. The company’s focus on integrating advanced analytics and data-driven approaches allows for the continuous improvement of their diagnostic solutions, ultimately contributing to more effective healthcare solutions and better management of diseases.

Switzerland

Liquid biopsies provide better therapy options for more patients.

Hedera Dx is on a mission to provide the next billion people with access to modern cancer care.
We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring.
Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment.

Hedera Dx

Company Details